関節リウマチに対するＬＣＡＰ療法においてＣＲＰ値，ＤＡＳ２８‐ＣＲＰの改善に影響を及ぼす因子

DOI 被引用文献2件 参考文献14件

書誌事項

タイトル別名
  • Which Factors Affect CRP Level and DAS28-CRP Improvement in LCAP Therapy for Rheumatoid Arthritis Patients?

この論文をさがす

抄録

Objective: To investigate the effect of LCAP therapy for RA patients, we examined CRP level and DAS28-CRP levels and discussed the factors that affect the results.<BR>Methods: Seventeen RA patients (4 males and 13 females) with a mean age of 62.5 years, and a mean duration of illness of 11 years underwent LCAP therapy. Prior to LCAP therapy, their CRP levels were evaluated, with a mean of 5.44 mg/dL. The concomitant drugs were PSL for 14 patients, SASP for one patient, MTX for nine patients, Bc for two patients, MZR for one patient, LEF for one patient, ACT for one patient, and GST for one patient. DAS28-CRP was evaluated in 13 patients. CRP level (n=17) and DAS28-CRP scores (n=13) before and after the LCAP therapy were compared, and correlations with patients' background and status of complications were investigated. Statistical significance was analyzed by using multiple regression for the correlation between patients' background and therapeutic results, and Wilcoxon's signed-rank test for CRP level and DAS28-CRP as to various factors influencing the results.<BR>Results: CRP levels decreased by 20% or more in 9 of the17 patients (52.9%), and for DAS28-CRP, improvement of a moderate response or more was seen in 7 of the 13 patients (53.8%) . Combined use of MTX was defined as a factor that affected the treatment results. Comparison of CRP levels before and after LCAP therapy showed that in the MTX combination treatment group, there was a decrease in CRP level (p=.0504) and significant improvement in DAS28-CRP (p=.0280) . There was no complication due to LCAP therapy.<BR>Conclusion: LCAP therapy had no serious adverse effects, and is worth trying before biological preparations.

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (14)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ